Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
